Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine

AIDS

Volumn 15, Issue 10, 2001, Pages 1269-1274

  Conway, B ^a   Wainberg, M A ^a   Hall, D ^a   Harris, M ^a   Reiss, P ^a   Cooper, D ^a   Vella, S ^a   Curry, R ^a   Robinson, P ^a   Lange, J M A ^a   Montaner, J S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Combination therapy; Didanosine; Drug resistance; HIV; Nevirapine; Zidovudine

Indexed keywords

DIDANOSINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATION RATE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0035816374     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107060-00008     Document Type: Article

References (13)

1. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel
2. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. 3
4. Suppression of plasma viral load below 20 copies/ml is required to achieve long-term response to therapy
5. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
6. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
7. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
8. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
9. The accuracy and reproducibility of high throughout HIV-1 resistance testing under EN45001 and CLIA accreditation labels
10. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay
11. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
12. Novel amino acid change influencing susceptibility to nevirapine detected in primary HIV infection
13. Baseline prevalence of mutations linked to NNRTI resistance in patients enrolled in clinical studies of efavirenz